ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9–27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine The...

por Burkbauer, Laura, Goldbach, Macy M., Tchou, Julia C.
Publicado 2021

Awareness of link between obesity and breast cancer risk is associated with willingness to participate in weight loss intervention

por Burkbauer, Laura, Goldbach, Macy, Huang, Cassie, Lewandowski, Julia, Krouse, Robert, Allison, Kelly, Tchou, Julia
Publicado 2022

Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)

por Goldbach, Macy M., Burkbauer, Laura, Bharani, Tina, Williams, Austin D., Keele, Luke, Rothman, Jami, Jankowitz, Rachel, Tchou, Julia C.
Publicado 2021

ASO Visual Abstract: Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)

por Goldbach, Macy M., Burkbauer, Laura, Bharani, Tina, Williams, Austin D., Keele, Luke, Rothman, Jami, Jankowitz, Rachel, Tchou, Julia C.
Publicado 2021

Correction to: Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)

por Goldbach, Macy M., Burkbauer, Laura, Bharani, Tina, Williams, Austin D., Keele, Luke, Rothman, Jami, Jankowitz, Rachel, Tchou, Julia C.
Publicado 2021